YolTech Therapeutics Secures Nearly RMB 500 Million in Series C Funding to Advance 'One-Time Treatment, Lifelong Cure' In Vivo Gene Editing Pipeline

YolTech Therapeutics Announces Completion of Nearly RMB 500 Million in Series C FinancingYolTech Therapeutics announced today the completion of its Series C financing round, raising nearly RMB 500 million. The round was led by Loyal Valley Capital, with participation from prominent institutions including SSCILF, Minjin Investment, and Deyue Investment. Existing shareholders Xianfeng Qiyun, Yuanyi, and Tianchuang Capital also increased their investments by following on in this round.

YolTech Therapeutics, established in 2021, is dedicated to developing in vivo gene-editing therapeutics with the potential for “one-time dosing, lifelong cure.”

YolTech Therapeutics boasts a world-class gene editing R&D team and has independently established a high-throughput platform for the discovery and evolution of editors, as well as a non-viral LNP delivery platform targeting various tissues and organs. The company has developed a series of gene editors and LNP delivery systems with independent global intellectual property rights. YolTech Therapeutics currently has six pipelines in clinical development, making it the company with the largest number of in vivo gene editing pipelines in clinical stages worldwide.

In 2024, YOLT-201, an LNP-based in vivo gene editing therapy for ATTR amyloidosis independently developed by YolTech Therapeutics, became the first drug of its kind in China to enter registration-enabling clinical trials. To date, dosing has been completed for all patients in the Phase 1/2a clinical trial.

In 2025, the FDA approved YolTech Therapeutics’ YOLT-203, a treatment for primary hyperoxaluria, to enter pivotal clinical trials in the United States. Furthermore, YolTech’s pipeline targeting common conditions such as hypercholesterolemia and alpha-1 antitrypsin deficiency, as well as other critical diseases, has also advanced into clinical stages, demonstrating favorable safety and efficacy profiles.

Loyal Valley Capital, the lead investor in this round, stated:“In recent years, the field of in vivo gene editing has seen continuous breakthroughs globally. YolTech Therapeutics has demonstrated remarkable innovation capabilities and clinical translation speed in this domain. With multiple pipelines advancing into late-stage clinical trials worldwide and generating encouraging data, the company fully showcases the immense potential of indigenous Chinese innovation, positioning its technology platform to become an international leader. Loyal Valley Capital maintains a long-term bullish outlook on YolTech’s innovative potential in frontier biomedicine and looks forward to the company accelerating the clinical application and commercialization of its gene-editing therapies, thereby benefiting patients across China and around the world.”

Wu Yuxuan, Founder of YolTech Therapeutics, stated:“We extend our heartfelt gratitude to new investors, including Loyal Valley Capital (LVC), for their strong support, and thank all existing shareholders for their long-term commitment and continued trust. Bolstered by multiple rounds of capital investment, YolTech Therapeutics has maintained a leading position in the global in vivo gene editing sector. Moving forward, we will leverage our dual-core platforms of proprietary original editors and lipid nanoparticle (LNP) delivery to accelerate the advancement of multiple core pipelines into global multicenter confirmatory clinical trials, expedite commercialization efforts, and deepen our focus on developing novel in vivo gene editing therapies that offer ‘one-time dosing, lifelong cure.’ We are committed to overcoming challenges in treating a range of rare diseases and major chronic conditions with innovative therapies, ensuring that next-generation in vivo gene editing treatments benefit patients worldwide as soon as possible.”